| 薛亚婷，金川，宋叶，江鹏，石燕霞▲.重组人血管内皮抑制素注射液3天静脉泵注与14天静脉滴注方案对肺癌患者临床疗效与不良反应的效果[J].中国医药科学,2023,(20):49-53 基金项目: |
| 重组人血管内皮抑制素注射液3天静脉泵注与14天静脉滴注方案对肺癌患者临床疗效与不良反应的效果 |
| Comparison of clinical efficacy and adverse reactions between 3-day pumping and 14-day intravenous dripping regimens of recombinant human endostatin injection in patients with lung cancer |
| |
| DOI： |
| 中文关键词: 重组人血管内皮抑制素；非小细胞肺癌；静脉泵注；治疗效果；安全性 |
| 英文关键词:Recombinant human endostatin; Non-small cell lung cancer; Intravenous pumping; Treatment effect; Safety |
| 作者 | 单位 | | 薛亚婷，金川，宋叶，江鹏，石燕霞▲ | 广州医科大学附属肿瘤医院内四科，广东广州 510095 |
|
| 摘要点击次数: 183 |
| 全文下载次数: 171 |
| 中文摘要: |
| [摘要] 目的 比较分析重组人血管内皮抑制素注射液（Endostatin）3 d静脉泵注方案与14 d静脉滴注方案对于局部晚期或晚期肺鳞癌或腺癌患者的临床疗效与不良反应。 方法 随机选取2010年1月至2022年8月在广州医科大学附属肿瘤医院就诊并使用Endostatin的50例ⅢB期/ⅢC期/Ⅳ期肺鳞癌或腺癌患者，按Endostatin给药方式分为两组，其中23例患者使用Endostatin 7.5 mg/m2静脉滴注+铂类化疗药物，连续14 d，为对照组（DIV组）；27例患者使用Endostatin 210 mg持续72 h静脉泵注+铂类化疗药物，为观察组（CIV组），比较两组的治疗效果、不良反应及住院天数。 结果 DIV组客观有效率（ORR）为34.8%，CIV组ORR为33.3%，DIV组疾病控制率（DCR）为73.9%，CIV组DCR为85.2%，两组之间ORR、DCR差异均无统计学意义（χ2=0.012，P=0.914；χ2=0.408，P=0.523）。毒副反应中肝功能异常、中性粒细胞下降、贫血、血小板下降、心电图异常、皮疹、咳嗽等不良反应差异无统计学意义（P > 0.05）；DIV组住院天数为（15.8±3.6）d，CIV组住院天数为（5.7±1.3）d，差异有统计学意义（t=13.562，P=0.001）。 结论 Endostatin说明书标准使用方案为14 d静脉滴注，本研究证明3 d持续静脉泵注与14 d静脉滴注治疗效果、不良反应差异无统计学意义，可缩短患者住院时间，提高患者依从性，为临床治疗提供一种选择。 |
| 英文摘要: |
| [Abstract] Objective To compare and analyze the clinical efficacy and adverse reactions of recombinant human endostatin injection (Endostatin) with a 3-day intravenous pumping regimen and a 14-day intravenous dripping regimen for locally advanced or advanced lung squamous cell carcinoma or adenocarcinoma patients. Methods A total of 50 patients with lung squamous cell carcinoma or adenocarcinoma in phases ofⅢB/ⅢC/Ⅳwho were treated with Endostatin at the Affiliated Cancer Hospital and Institution of Guangzhou Medical University from January 2010 to August 2022 were randomly selected and divided into two groups according to the administration method of Endostatin. 23 patients were treated with Endostatin 7.5 mg/m2 intravenous dripping and platinum-based chemotherapy drugs for 14 consecutive days, and were divided as a control group (DIV); 27 patients were treated with 210 mg Endostatin intravenous pumping and platinum-based chemotherapy drugs for 72 hours, were divided as an observation group (CIV). The treatment efficacy, adverse reactions, and length of hospital stay were compared between the two groups. Results The objective response rate (ORR) was 34.8% in the DIV group, 33.3% in the CIV group, disease control rate (DCR) was 73.9% in the DIV group, and 85.2% in the CIV group. There was no statistically significant difference in ORR, DCR between the two groups (χ2=0.012, P=0.914; χ2=0.408, P=0.523). There was no statistically significant difference in adverse reactions such as abnormal liver function, neutropenia, anemia, thrombocytopenia, abnormal electrocardiogram, rash, cough, etc. among the toxic side effects (P > 0.05). The length of stay in the DIV group was (15.8±3.6)d, while the length of stay in the CIV group was (5.7±1.3)d, with a statistically significant difference (t=13.562, P=0.001). Conclusion The standard usage regimen for Endostatin instructions is the 14-day intravenous dripping. This study demonstrates that there is no statistically significant difference in the treatment effect and adverse reactions between three days of continuous intravenous pumping and 14 days of intravenous dripping. It can shorten patient hospital stay, improve patient compliance, and provide a choice for clinical treatment. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
.jpg)